Views: 0 Author: Site Editor Publish Time: 2026-01-09 Origin: Site
In the UK's world-class pharmaceutical manufacturing sector, 2026 marks a pivotal year for the supply of high-purity oncological building blocks. 4-Amino-2-(trifluoromethyl)benzonitrile (CAS No. 654-70-6) stands at the forefront of this demand. As the structural foundation for second-generation androgen receptor antagonists like Bicalutamide and Enzalutamide, its importance in treating metastatic castration-resistant prostate cancer (CRPC) cannot be overstated.
The inclusion of the trifluoromethyl (-CF3) group at the 2-position significantly enhances the molecule's metabolic stability and binding affinity. This post examines the industrial criticalities of this compound and provides a definitive guide to the Top 8 Manufacturers in the UK, led by the excellence of EASTFINE.
The 2026 outlook for CAS 654-70-6 is driven by several key factors within the UK and European pharmaceutical hubs:
As a standard of care for prostate cancer, the global demand for Bicalutamide remains robust. The synthesis of this API requires the precise acylation and oxidation of the 4-amino-2-trifluoromethyl scaffold, making the purity of the starting intermediate the primary determinant of final yield.
Newer synthetic routes for Enzalutamide increasingly favor CAS 654-70-6 as a safer, more stable starting material compared to hazardous isothiocyanate alternatives. This shift has led to a surge in industrial-scale requirements for the benzonitrile derivative.
Recent studies have identified that derivatives synthesized from this intermediate are potential candidates for inhibiting endothelial cell growth in breast cancer models, expanding the compound's utility beyond traditional prostate cancer therapy.
Manufacturing 4-Amino-2-(trifluoromethyl)benzonitrile at an industrial scale is a significant technical challenge that requires mastery over regioselective chemistry:
Positioning the trifluoromethyl group specifically at the 2-position relative to the nitrile is vital. Even trace amounts of isomers (such as the 3-trifluoromethyl analog) will lead to inactive or toxic final drug products that fail UK MHRA standards.
The nitrile group (-CN) must remain intact during the reduction or substitution of the amino group. This requires ultra-precise reaction monitoring and specialized catalytic systems to avoid ring-opening byproducts.
For oncology APIs, residual heavy metals (like Palladium or Copper) must be kept below 10 ppm to ensure compliance with the British Pharmacopoeia (BP).
Procurement teams in the UK biotech corridor prioritize the following when sourcing CAS 654-70-6:
Comprehensive HPLC, GC-MS, and NMR data for every batch to ensure identity and purity.
A guarantee of ≥ 99.0% purity with negligible positional isomer content.
As an oncology intermediate, any disruption in the supply chain can delay life-saving drug production, making manufacturer reliability paramount.
The UK remains a critical hub for pharmaceutical excellence. Here are the top 8 players providing high-purity 4-Amino-2-(trifluoromethyl)benzonitrile:
EASTFINE is the gold standard for 4-Amino-2-(trifluoromethyl)benzonitrile. We lead the UK market through:
We consistently achieve an assay of ≥ 99.5%, significantly exceeding the industry average.
Our dedicated shipping routes to the UK ensure that moisture-sensitive powders arrive in optimal condition, supported by full customs documentation for the post-Brexit environment.
Our legacy provides us with a proprietary synthesis route that minimizes waste and ensures the lowest ppm of heavy metal impurities in the industry.
EASTFINE’s green chemistry protocols ensure that our trifluoromethylation processes meet 2026 sustainability standards, a critical factor for UK pharmaceutical partners.
A cornerstone of the UK chemical industry, Fluorochem is recognized for its vast inventory of fluorinated aromatics and serves as a primary source for UK-based R&D teams.
Specializing in nitrogen-containing building blocks, Apollo provides high-quality intermediates for medicinal chemistry with a strong focus on the UK biotech sector.
Part of the Navin Fluorine group, they leverage deep expertise in fluorination to provide a consistent supply of trifluoromethylated benzonitriles to the European market.
A global giant with significant UK operations, providing pharmaceutical-grade reagents with a high level of analytical documentation and reliable distribution.
Known for their high-end analytical standards, they are a preferred source for reference materials and pilot-scale synthesis in regulated environments.
A specialist in custom synthesis, Key Organics provides high-purity heterocyclic building blocks for drug discovery programs across the British Isles.
As the largest independent British supplier of laboratory chemicals, SLS offers reliable distribution of intermediates for academic, clinical, and hospital research.
In the production of oncology medications, the purity of your intermediate is the foundation of patient safety. EASTFINE provides the technical security that global pharma leaders demand.
Our "Designed-for-Quality" approach ensures that you never have to worry about isomer contamination in your final API.
Whether you need 1 kg for a pilot run or 10 tons for commercial manufacturing, EASTFINE delivers with consistent analytical precision.
We provide the DMF-ready documentation you need to clear UK MHRA and EMA audits effortlessly.
As the demand for 4-Amino-2-(trifluoromethyl)benzonitrile (CAS No. 654-70-6) continues to rise, the importance of a reliable, high-purity source is paramount. EASTFINE remains the #1 partner for UK pharmaceutical firms, offering the perfect blend of innovation, purity, and supply chain security to power life-saving oncology treatments.
简体中文
